Peginterferon and TIL Therapy for Metastatic Melanoma
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
Adoptive T cell therapy with tumor infiltrating lymphocytes (TIL) has achieved impressive
clinical results with durable complete responses in patients with metastatic melanoma. The
TILs are isolated from the patients own tumor tissue followed by in vitro expansion and
activation for around 4-6 weeks. Before TIL infusion the patients receive 1 week of
preconditioning chemotherapy with cyclophosphamide and fludarabine. After TIL infusion
Interleukin-2 are administered to support T cell activation and proliferation in vivo.
In this trial the therapy is combined with peginterferon (the pegylated form of interferon
alpha 2b). Interferon alpha has immunomodulatory effects and is known to upregulate HLA
expression on melanoma cells and are hypothesized to synergize with TIL therapy.